Deutsche Bank Defends Gilead Sciences (GILD) on Sector Setback
Tweet Send to a FriendGet Alerts GILD Hot Sheet
Price: $55.81 +0.59%
Rating Summary:
17 Buy, 6 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
17 Buy, 6 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade GILD Now!
Deutsche Bank commented on Gilead Sciences (NASDAQ: GILD) following news in the sector from Idenix Pharmaceuticals Inc. (Nasdaq: IDIX), which said the FDA placed hepatitis C drug IDX184 on partial clinical hold due to a serious cardiac-related adverse event.
The firm said they spoke with GILD management and the company believes the concerns with IDX184 are drug-specific, not on entire nuke class. GILD said they have not been contacted by the FDA.
The analyst comments: "Notably, GS-7977 has been dosed in over 1000 patients for 12 weeks. Recall, IDX 184 had only been tested in 67 patients for 2 weeks. Furthermore, GS-7977 has already successfully completed a thorough QTC study. This provides us with significant comfort that GS-7977 does not have cardiac issues. From speaking with different thought leaders in the HCV space, it is our sense that the FDA becomes more comfortable when >200 patients have been dosed. Gilead reiterated that it paid $11B for GS-7977 due to its significant safety database."
The firm reiterated their Buy rating and price target of $68.00.
For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.
Shares of Gilead Sciences closed at $57.97 yesterday, with a 52 week range of $34.45-$58.84.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The firm said they spoke with GILD management and the company believes the concerns with IDX184 are drug-specific, not on entire nuke class. GILD said they have not been contacted by the FDA.
The analyst comments: "Notably, GS-7977 has been dosed in over 1000 patients for 12 weeks. Recall, IDX 184 had only been tested in 67 patients for 2 weeks. Furthermore, GS-7977 has already successfully completed a thorough QTC study. This provides us with significant comfort that GS-7977 does not have cardiac issues. From speaking with different thought leaders in the HCV space, it is our sense that the FDA becomes more comfortable when >200 patients have been dosed. Gilead reiterated that it paid $11B for GS-7977 due to its significant safety database."
The firm reiterated their Buy rating and price target of $68.00.
For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.
Shares of Gilead Sciences closed at $57.97 yesterday, with a 52 week range of $34.45-$58.84.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Bulls and Bears Do Battle in Aeropostale (ARO); Turnaround Intact?
- Janney Capital Boosts PT on Gap (GPS) Post Q1
- Toll Bros. (TOL) Estimates/PT Raised at Compass Point
Create E-mail Alert Related Categories
Analyst Comments, Trader TalkRelated Entities
Deutsche Bank
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
